Foresight Diagnostics
@foresight-dx.bsky.social
Leader in ultra-sensitive #ctDNA #MRD detection to improve outcomes in cancer patients.
#precisiononcology #lymphoma #NSCLC #breastcancer
#precisiononcology #lymphoma #NSCLC #breastcancer
The Foresight team is excited to be at #ASH2025! Catch our Oral Presentation on #ForesightCLARITY in #DLBCL surveillance on Sun., Dec. 7 from 10:45–11:00am ET.
Stop by booth #2165 to meet our executive team and clinical experts or reach out to BD@foresight-dx.com to connect.
Stop by booth #2165 to meet our executive team and clinical experts or reach out to BD@foresight-dx.com to connect.
November 25, 2025 at 2:10 PM
The Foresight team is excited to be at #ASH2025! Catch our Oral Presentation on #ForesightCLARITY in #DLBCL surveillance on Sun., Dec. 7 from 10:45–11:00am ET.
Stop by booth #2165 to meet our executive team and clinical experts or reach out to BD@foresight-dx.com to connect.
Stop by booth #2165 to meet our executive team and clinical experts or reach out to BD@foresight-dx.com to connect.
Join Dr. David Kurtz of Foresight Diagnostics as he reviews Allogene’s phase 2 ALPHA3 trial of cema-cel, an allogeneic CAR T in MRD+ LBCL after frontline therapy, and CLARITY™ MRD data, trial updates, and milestones. Add to calendar: calendarlink.com/event/wpYmu
November 21, 2025 at 2:27 PM
Join Dr. David Kurtz of Foresight Diagnostics as he reviews Allogene’s phase 2 ALPHA3 trial of cema-cel, an allogeneic CAR T in MRD+ LBCL after frontline therapy, and CLARITY™ MRD data, trial updates, and milestones. Add to calendar: calendarlink.com/event/wpYmu
Foresight is pushing the boundaries of cancer diagnostics. Co-founders Jake Chabon and Max Diehn and Fierce Biotech’s Chris Hayden discuss how #MRD testing is transforming care and our ultrasensitive approach focused on clinically-actionable decisions for patients: bit.ly/49sQOib
Inside Foresight’s Mission to Redefine Cancer Monitoring
| Discover how Foresight Diagnostics is pushing MRD detection to new limits with its ultrasensitive technology that has the potential to unlock new actionable insights.
bit.ly
November 20, 2025 at 3:02 PM
Foresight is pushing the boundaries of cancer diagnostics. Co-founders Jake Chabon and Max Diehn and Fierce Biotech’s Chris Hayden discuss how #MRD testing is transforming care and our ultrasensitive approach focused on clinically-actionable decisions for patients: bit.ly/49sQOib
We’re honored to be recognized as one of DeloitteUS’s 2025 Fast 500 companies! As we continue advancing cancer drug development and patient care through innovative diagnostics combining precision genomics and cutting-edge science, we’re inspired to keep pushing boundaries.
November 19, 2025 at 3:08 PM
We’re honored to be recognized as one of DeloitteUS’s 2025 Fast 500 companies! As we continue advancing cancer drug development and patient care through innovative diagnostics combining precision genomics and cutting-edge science, we’re inspired to keep pushing boundaries.
Last night, our team attended the Colorado Avalanche’s Hockey Fights Cancer game with UCHealth - a powerful night of honoring cancer warriors and supporting those affected by cancer. Proceeds benefited the American Cancer Society.
#ForesightCLARITY #Oncology
#ForesightCLARITY #Oncology
November 17, 2025 at 8:29 PM
Last night, our team attended the Colorado Avalanche’s Hockey Fights Cancer game with UCHealth - a powerful night of honoring cancer warriors and supporting those affected by cancer. Proceeds benefited the American Cancer Society.
#ForesightCLARITY #Oncology
#ForesightCLARITY #Oncology
Foresight is pushing the boundaries of cancer diagnostics. CBO John Truesdell and Fierce Biotech's Chris Hayden discuss how our ultrasensitive #MRD approach can enable clinically-actionable decisions in oncology: youtu.be/OihBGDqEN2s
#ctdna #mrd
#ctdna #mrd
Foresight Diagnostics executive sees MRD testing as future of cancer care
YouTube video by Fierce Life Sciences
youtu.be
November 12, 2025 at 3:55 PM
Foresight is pushing the boundaries of cancer diagnostics. CBO John Truesdell and Fierce Biotech's Chris Hayden discuss how our ultrasensitive #MRD approach can enable clinically-actionable decisions in oncology: youtu.be/OihBGDqEN2s
#ctdna #mrd
#ctdna #mrd
Will we see you at #ASH25? Foresight will present the first real-world study of ctDNA dynamics in treated #LBCL, showcasing how #ultrasensitive MRD detection can guide personalized treatment. Excited to connect on the next stage of MRD-driven care: bit.ly/47kdmQE
November 3, 2025 at 6:19 PM
Will we see you at #ASH25? Foresight will present the first real-world study of ctDNA dynamics in treated #LBCL, showcasing how #ultrasensitive MRD detection can guide personalized treatment. Excited to connect on the next stage of MRD-driven care: bit.ly/47kdmQE
Spirits are high in the office this week with a little Halloween fun! Our team came together for some friendly competition during our costume contest, sharing laughs and creativity, along with some impressive outfits. Thanks to everyone who joined in!
October 31, 2025 at 8:16 PM
Spirits are high in the office this week with a little Halloween fun! Our team came together for some friendly competition during our costume contest, sharing laughs and creativity, along with some impressive outfits. Thanks to everyone who joined in!
Welcome Carrina Cappadona to the team! As our new VP of Patient and Client Experience, Carinna will lead efforts to ensure that patients, clinicians, and providers are supported as we work to develop innovative diagnostic tests to advance cancer drug development and patient care.
October 21, 2025 at 3:11 PM
Welcome Carrina Cappadona to the team! As our new VP of Patient and Client Experience, Carinna will lead efforts to ensure that patients, clinicians, and providers are supported as we work to develop innovative diagnostic tests to advance cancer drug development and patient care.
Our Foresight CLARITY™ MRD platform detects the presence of #MRD from circulating tumor DNA (ctDNA) with sensitivity to multiple cancers.
Learn about how Foresight CLARITY™ is shaping the next-gen of cancer monitoring: bit.ly/4mpDDRW
#UltrasensitiveScience
Learn about how Foresight CLARITY™ is shaping the next-gen of cancer monitoring: bit.ly/4mpDDRW
#UltrasensitiveScience
October 17, 2025 at 2:24 PM
Our Foresight CLARITY™ MRD platform detects the presence of #MRD from circulating tumor DNA (ctDNA) with sensitivity to multiple cancers.
Learn about how Foresight CLARITY™ is shaping the next-gen of cancer monitoring: bit.ly/4mpDDRW
#UltrasensitiveScience
Learn about how Foresight CLARITY™ is shaping the next-gen of cancer monitoring: bit.ly/4mpDDRW
#UltrasensitiveScience
Excited to attend #ESMO2025 in Berlin!
Foresight team members will be onsite connecting with experts on the latest breakthroughs in #oncology. Curious about our #MRD detection technology, #ForesightCLARITY? Let’s connect!
Reach out here: bit.ly/4mZE7yK
#BeyondClarity #UltrasensitiveScience
Foresight team members will be onsite connecting with experts on the latest breakthroughs in #oncology. Curious about our #MRD detection technology, #ForesightCLARITY? Let’s connect!
Reach out here: bit.ly/4mZE7yK
#BeyondClarity #UltrasensitiveScience
October 9, 2025 at 2:00 PM
Excited to attend #ESMO2025 in Berlin!
Foresight team members will be onsite connecting with experts on the latest breakthroughs in #oncology. Curious about our #MRD detection technology, #ForesightCLARITY? Let’s connect!
Reach out here: bit.ly/4mZE7yK
#BeyondClarity #UltrasensitiveScience
Foresight team members will be onsite connecting with experts on the latest breakthroughs in #oncology. Curious about our #MRD detection technology, #ForesightCLARITY? Let’s connect!
Reach out here: bit.ly/4mZE7yK
#BeyondClarity #UltrasensitiveScience
Curious how ctDNA could reshape care for aggressive cancers like #DLBCL? Hear from co-founder Ash Alizadeh on Blood Cancer Talks on its transformative potential, from advances in detection to breakthrough clinical data. Listen here: bit.ly/4mBkyfr
Episode 65. Circulating Tumor DNA in DLBCL with Dr. Ash Alizadeh and Dr. David Russler-Germain
Podcast Episode · Blood Cancer Talks · 09/24/2025 · 53m
bit.ly
October 2, 2025 at 3:14 PM
Curious how ctDNA could reshape care for aggressive cancers like #DLBCL? Hear from co-founder Ash Alizadeh on Blood Cancer Talks on its transformative potential, from advances in detection to breakthrough clinical data. Listen here: bit.ly/4mBkyfr
Excited to join #FierceBiotechWeek! Our CBO John Truesdell and Allogene Therapeutics CMO Zachary Roberts will discuss how next-gen #MRD is reshaping oncology, driving personalized care, advancing therapies, and informing decisions to improve outcomes. Register here: bit.ly/4nk0C1A
September 30, 2025 at 3:32 PM
Excited to join #FierceBiotechWeek! Our CBO John Truesdell and Allogene Therapeutics CMO Zachary Roberts will discuss how next-gen #MRD is reshaping oncology, driving personalized care, advancing therapies, and informing decisions to improve outcomes. Register here: bit.ly/4nk0C1A
The Foresight team was proud to support Blood Cancer United at our local #LightTheNight Walk! We sponsored the walkway and cheered on patients, survivors, families, and supporters. It was an inspiring night honoring those impacted by blood cancers and funding life-saving research.
September 29, 2025 at 3:50 PM
The Foresight team was proud to support Blood Cancer United at our local #LightTheNight Walk! We sponsored the walkway and cheered on patients, survivors, families, and supporters. It was an inspiring night honoring those impacted by blood cancers and funding life-saving research.
We had a great time at World CB & CDx Summit this week! A highlight was hosting a lunch & learn with QIAGEN, where we explored opportunities for MRD-driven companion diagnostic development and distribution.
Connect with our BD team to learn more about us: bit.ly/4mZE7yK
Connect with our BD team to learn more about us: bit.ly/4mZE7yK
September 26, 2025 at 6:25 PM
We had a great time at World CB & CDx Summit this week! A highlight was hosting a lunch & learn with QIAGEN, where we explored opportunities for MRD-driven companion diagnostic development and distribution.
Connect with our BD team to learn more about us: bit.ly/4mZE7yK
Connect with our BD team to learn more about us: bit.ly/4mZE7yK
We’re thrilled to welcome McKenzie Carlisle, PhD, to the Foresight team! As our new Senior Director of Regulatory Operations and Compliance, she’ll lead regulatory strategy for our IVD pipeline, helping drive innovative diagnostics to advance oncology drug development and patient care.
September 25, 2025 at 2:07 PM
We’re thrilled to welcome McKenzie Carlisle, PhD, to the Foresight team! As our new Senior Director of Regulatory Operations and Compliance, she’ll lead regulatory strategy for our IVD pipeline, helping drive innovative diagnostics to advance oncology drug development and patient care.
On #WorldCancerResearchDay, we reaffirm our goal to give patients actionable data when it matters most. With Foresight CLARITY™, powered by our PhasED-Seq™ technology, we aim to uncover residual disease at key points in treatment. Learn more about us: bit.ly/4pwH3EY
September 24, 2025 at 2:43 PM
On #WorldCancerResearchDay, we reaffirm our goal to give patients actionable data when it matters most. With Foresight CLARITY™, powered by our PhasED-Seq™ technology, we aim to uncover residual disease at key points in treatment. Learn more about us: bit.ly/4pwH3EY
The Foresight team is excited to join Blood Cancer United's #LightTheNight walk in Denver on Sept. 25 to honor and support those impacted by #bloodcancer. Walk with us, or find an event near you to help raise funds for life-saving research. Sign up here: bit.ly/3IjzEYS
September 22, 2025 at 3:16 PM
The Foresight team is excited to join Blood Cancer United's #LightTheNight walk in Denver on Sept. 25 to honor and support those impacted by #bloodcancer. Walk with us, or find an event near you to help raise funds for life-saving research. Sign up here: bit.ly/3IjzEYS
Looking forward to the Liquid Biopsy Symposium! Michiel Pegtel, PhD and HOVON will present on the value of Foresight CLARITY™ #MRD at end of #DLBCL therapy in a real-world cohort and founder Max Diehn, MD, PhD, will present on advances in liquid biopsies: bit.ly/4mSKNPL
September 17, 2025 at 6:07 PM
Looking forward to the Liquid Biopsy Symposium! Michiel Pegtel, PhD and HOVON will present on the value of Foresight CLARITY™ #MRD at end of #DLBCL therapy in a real-world cohort and founder Max Diehn, MD, PhD, will present on advances in liquid biopsies: bit.ly/4mSKNPL
Excited to be at the upcoming World CB & CDx Summit! Meet us to learn about our technology for detecting #MRD with unmatched sensitivity in cancer types. Ask about our QIAGEN partnership to develop CDx kits for #lymphoma and our global CDx capabilities. More details: world-cdx.com
September 17, 2025 at 1:56 PM
Excited to be at the upcoming World CB & CDx Summit! Meet us to learn about our technology for detecting #MRD with unmatched sensitivity in cancer types. Ask about our QIAGEN partnership to develop CDx kits for #lymphoma and our global CDx capabilities. More details: world-cdx.com
Reflecting on a successful #WCLC25! Our team shared our work with University Health Network Toronto on advancing ctDNA analysis in #NSCLC with Foresight CLARITY™ and connected with colleagues, collaborators and others dedicated to improving outcomes in #lungcancer. More details: bit.ly/4gmQh2t
September 15, 2025 at 5:15 PM
Reflecting on a successful #WCLC25! Our team shared our work with University Health Network Toronto on advancing ctDNA analysis in #NSCLC with Foresight CLARITY™ and connected with colleagues, collaborators and others dedicated to improving outcomes in #lungcancer. More details: bit.ly/4gmQh2t
On #WLAD we recognize challenges patients face post-treatment: ~30% of #DLBCL patients relapse, often taking 1–2 years to confirm with current methods. Foresight CLARITY™ seeks to detect relapse sooner, enabling precise care. Learn more: bit.ly/45yFqgO #BloodCancerMonth
September 15, 2025 at 3:19 PM
On #WLAD we recognize challenges patients face post-treatment: ~30% of #DLBCL patients relapse, often taking 1–2 years to confirm with current methods. Foresight CLARITY™ seeks to detect relapse sooner, enabling precise care. Learn more: bit.ly/45yFqgO #BloodCancerMonth
How is research shaping the future of cancer care? Hear from our CEO & CMO on Mendelspod on Foresight’s origin story, our next-gen #MRD testing with unmatched sensitivity, detecting relapse earlier, and what’s next for cancer care. Listen here: bit.ly/46pUm1A
#Oncology
#Oncology
Next-Gen MRD Testing: Foresight’s Leap in Sensitivity with Jake Chabon and Dave Kurtz
Catching a cancer relapse before any scan could see it is the ultimate goal for minimal residual disease or MRD testing.
bit.ly
September 12, 2025 at 1:29 PM
How is research shaping the future of cancer care? Hear from our CEO & CMO on Mendelspod on Foresight’s origin story, our next-gen #MRD testing with unmatched sensitivity, detecting relapse earlier, and what’s next for cancer care. Listen here: bit.ly/46pUm1A
#Oncology
#Oncology
Company Announcement: Foresight Diagnostics and Roche Enter Licensing Agreement for PhasED-Seq™ Technology in Non-Hodgkin’s Lymphoma. The Agreement Closes the Litigation Between the Parties. More information: bit.ly/46fSoki
#MRD #Oncology
#MRD #Oncology
September 5, 2025 at 6:08 PM
Company Announcement: Foresight Diagnostics and Roche Enter Licensing Agreement for PhasED-Seq™ Technology in Non-Hodgkin’s Lymphoma. The Agreement Closes the Litigation Between the Parties. More information: bit.ly/46fSoki
#MRD #Oncology
#MRD #Oncology
Our team is at #WCLC25 this weekend! We’re sharing data with University Health Network Toronto on ctDNA analysis from the ctDNA-Lung-DETECT study in #NSCLC using Foresight CLARITY™, our ultrasensitive next-gen assay, showing high #MRD detection. Details: bit.ly/4g9ynQN
September 5, 2025 at 2:48 PM
Our team is at #WCLC25 this weekend! We’re sharing data with University Health Network Toronto on ctDNA analysis from the ctDNA-Lung-DETECT study in #NSCLC using Foresight CLARITY™, our ultrasensitive next-gen assay, showing high #MRD detection. Details: bit.ly/4g9ynQN